Results from SOFIE’s Phase 2 diagnostic study on [18F]FAPI-74 PET were presented to the oncological community at the esteemed ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco January 8-10, 2026.

The multi-center trial showed that [18F]FAPI-74 PET detects FAP expression and presence of disease in cancers of the gastrointestinal tract, with high positive predictive values for both sensitivity and specificity of metastatic disease.

The poster abstract can be found here.

Janna Laton, Director of Product Launch – FAPI, shares this recap from her time at ASCO GI.  Along with meeting medical oncologists and surgeons interested in FAPI, Janna spoke with patient advocacy groups to better understand their needs.